Organon OGN
NYSE OGN
$13.75 +0.01 (+0.07%)
At close: Aug 21, 2026 · 4:00 PM EDT

Organon (OGN) Amortizatization of Intangibles (2020 - 2026)

Organon (OGN) posted quarterly Amortizatization of Intangibles of $46.0 million for Q2 2026, down 13.21% year-over-year from $53.0 million in Q2 2025, and down 2.13% on a QoQ basis from $47.0 million in Q1 2026.

Organon (OGN) Amortizatization of Intangibles (2020 - 2026) Analysis & Trends

Organon has reported Amortizatization of Intangibles for 7 years, with the latest figure at $46.0 million in Q2 2026.

  • Amortizatization of Intangibles for Q2 2026 came in at $46.0 million, down 13.21% year-over-year; the trailing twelve-month figure through Jun 2026 was $195.0 million (up 7.73% YoY), and the FY2025 annual result was $205.0 million, up 41.38% from the prior year.
  • Amortizatization of Intangibles retreated to $46.0 million in Q2 2026, from $47.0 million in the prior quarter.
  • Over five years, Amortizatization of Intangibles peaked at $53.0 million in Q2 2025 and troughed at $28.0 million in Q1 2022.
  • A 5-year average of $37.5 million and a median of $33.5 million in 2024 frame the typical range for Amortizatization of Intangibles.
  • The widest annual swing landed in 2022, when Amortizatization of Intangibles declined 17.65%; it then surged 55.88% in 2025.
  • A 5-year view of Amortizatization of Intangibles shows it stood at $28.0 million in 2022, then changed by 0.0% to $28.0 million in 2023, then soared by 53.57% to $43.0 million in 2024, then climbed by 16.28% to $50.0 million in 2025, then slipped by 8.0% to $46.0 million in 2026.
  • Per Business Quant data, the three most recent Amortizatization of Intangibles figures were $46.0 million in Q2 2026, $47.0 million in Q1 2026, and $50.0 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Amortizatization of Intangibles (Qtr)
1 Johnson & Johnson 652.20 Bn 631.44 Bn 17.26 Bn -
2 AbbVie 469.51 Bn 462.94 Bn 12.70 Bn -
3 Merck 376.81 Bn 369.67 Bn 12.21 Bn 984.00 Mn
4 Novartis Ag 303.04 Bn 295.35 Bn 11.24 Bn -
5 Astrazeneca 257.61 Bn 252.71 Bn 12.86 Bn -
6 Amgen 237.37 Bn 223.38 Bn 7.24 Bn -
7 Gilead Sciences 181.73 Bn 178.55 Bn 6.22 Bn 600.00 Mn
8 Pfizer 159.66 Bn 147.96 Bn 10.94 Bn -
9 Gsk 106.24 Bn 102.07 Bn 8.24 Bn -
10 Organon 3.61 Bn 2.48 Bn 847.00 Mn 46.00 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 46.00 Mn
Jun 30, 2026 46.00 Mn
Mar 31, 2026 47.00 Mn
Mar 31, 2026 47.00 Mn
Dec 31, 2025 50.00 Mn
Dec 31, 2025 50.00 Mn
Sep 30, 2025 52.00 Mn
Sep 30, 2025 52.00 Mn
Jun 30, 2025 53.00 Mn
Jun 30, 2025 53.00 Mn
Mar 31, 2025 50.00 Mn
Mar 31, 2025 50.00 Mn
Dec 31, 2024 43.00 Mn
Dec 31, 2024 43.00 Mn
Sep 30, 2024 35.00 Mn
Sep 30, 2024 35.00 Mn
Jun 30, 2024 34.00 Mn
Jun 30, 2024 34.00 Mn
Mar 31, 2024 33.00 Mn
Mar 31, 2024 33.00 Mn